Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03245736 · OUTCOME

Number of Participants With Increased Cancer Antigen (CA 125) Levels

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. · Source last updated 2021-11-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Day 1 to Week 24 plus 30 days

What was measured

The number of participants with ovarian cancer whose levels of CA125 Antigen had increased since the end of the base trial are presented.

Groups in this outcome

Tisotumab Vedotin

Tisotumab vedotin was administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (once every 3 weeks). The trial ran until the investigator determined that the participant was no longer benefiting from treatment (ie, disease progression or unacceptable toxicity had occurred), the trial was terminated by the sponsor, or the participant withdrew consent. Each participant received the same dose that they were exposed to in the previous base trial.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Tisotumab Vedotin2

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Tisotumab Vedotin1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    units
    Participants
description
The number of participants with ovarian cancer whose levels of CA125 Antigen had increased since the end of the base trial are presented.
groups
  1. description
    Tisotumab vedotin was administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (once every 3 weeks). The trial ran until the investigator determined that the participant was no longer benefiting from treatment (ie, disease progression or unacceptable toxicity had occurred), the trial was terminated by the sponsor, or the participant withdrew consent. Each participant received the same dose that they were exposed to in the previous base trial.
    id
    OG000
    title
    Tisotumab Vedotin
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Day 1 to Week 24 plus 30 days
title
Number of Participants With Increased Cancer Antigen (CA 125) Levels
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice